HUTCHMED (China) Limited (AIM:HCM)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.86B |
| Revenue (ttm) | 503.39M |
| Net Income (ttm) | 30.14M |
| Shares Out | 854.88M |
| EPS (ttm) | 0.03 |
| PE Ratio | 68.23 |
| Forward PE | 30.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,456 |
| Average Volume | 67,842 |
| Open | 216.00 |
| Previous Close | 218.00 |
| Day's Range | 211.00 - 216.00 |
| 52-Week Range | 185.50 - 353.00 |
| Beta | 0.72 |
| RSI | 47.47 |
| Earnings Date | Jun 12, 2025 |
About HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ... [Read more]
Financial Performance
In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.
Financial numbers in USD Financial StatementsNews
Hutchmed weighs cancer drug’s supply-chain options amid US-China trade war
Blood-cancer medicine, manufactured in the US, won conditional approval for sale in mainland China last month.
HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma
— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED's fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025...
Intended Retirement of Independent Non-executive Directors and changes of composition of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Ruther...
US pharma restrictions won't affect Hutchmed operations, says CEO
Weiguo Su, CEO of Chinese pharma company HUTCHMED, talks about the company's latest earnings report, and why it's positioned to be 'sustainably profitable' from this point despite some external chall...
US pharma restrictions won't affect Hutchmed operations, says CEO
Weiguo Su, CEO of Chinese pharma company HUTCHMED, talks about the company's latest earnings report, and why it's positioned to be 'sustainably profitable' from this point despite some external challe...
HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025
— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO ® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address ...
Hutchmed spikes after cancer trial win despite 2024 revenue miss
HUTCHMED (China) Limited (HCM) Q4 2024 Earnings Call Transcript
HUTCHMED (China) Limited (NASDAQ:HCM) Q4 2024 Earnings Conference Call March 19, 2025 8:00 AM ET Company Participants David Ng - Head:IR Wei-Guo Su - CEO & Chief Scientific Officer Johnny Cheng - CFO...
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) reported 2024 earnings of 22 cents per ADS or 4 cents per share, down 59 cents or 12 cents a year ago. Sales fell 25% year over year to $630.20 mi...
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength
On Wednesday, Hutchmed (China) Limited (NASDAQ: HCM) reported 2024 earnings of 22 cents per ADS or 4 cents per share, down 59 cents or 12 cents a year ago. Sales fell 25% year over year to $630.20 mi...
HUTCHMED (China) Limited 2024 Q4 - Results - Earnings Call Presentation
The following slide deck was published by HUTCHMED (China) Limited in conjunction with their 2024 Q4 earnings call.
Hutchison GAAP EPADS of $0.22, revenue of $630.2M misses by $38.58M
Hutchison China MediTech reports FY GAAP EPS of $0.22 and revenue of $630.2M (-24.8% Y/Y), missing estimates by $38.58M.
HUTCHMED Reports 2024 Full Year Results and Provides Business Updates
65% oncology products revenue growth drove profitable operation and supported new ATTC platform 65% oncology products revenue growth drove profitable operation and supported new ATTC platform
HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 018...
HUTCHMED Completes Enrollment for Phase II Trial of Fanregratinib in IHCC Patients
HUTCHMED Completes Enrollment for Phase II Trial of Fanregratinib in IHCC Patients
HUTCHMED Announces that it has Completed Enrollment of a Phase II Registration Study of Fanregratinib (HMPL-453) for Intrahepatic Cholangiocarcinoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has completed enrollment of ...
HUTCHMED (China) Ltd (HCM) Appoints Alvin Wong as Independent Non-Executive Director
HUTCHMED (China) Ltd (HCM) Appoints Alvin Wong as Independent Non-Executive Director
HUTCHMED Appoints Alvin Wong as Independent Non-Executive Director
HUTCHMED Appoints Alvin Wong as Independent Non-Executive Director
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Wong Tak Wa...
HUTCHMED (China) Ltd (HCM) Announces Upcoming Financial Results Release
HUTCHMED (China) Ltd (HCM) Announces Upcoming Financial Results Release
HUTCHMED to Announce 2024 Final Results
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ende...
Despite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)
HUTCHMED (China) Ltd (HCM) Shares Gap Down to $13.87 on Jan 15
HUTCHMED (China) Ltd (HCM) Shares Gap Down to $13.87 on Jan 15
Hutchmed (HCM) Shares Drop Over 5.7% Amid Delayed Approvals
Hutchmed (HCM) Shares Drop Over 5.7% Amid Delayed Approvals
HUTCHMED (China) Ltd (HCM) Gains Full Approval for ORPATHYS® in China
HUTCHMED (China) Ltd (HCM) Gains Full Approval for ORPATHYS® in China